<DOC>
	<DOCNO>NCT00637611</DOCNO>
	<brief_summary>The primary objective study determine efficacy onsets action single-dose fexofenadine hydrochloride 180 mg montelukast sodium 10 mg relative placebo . Secondary objective compare safety efficacy fexofenadine hydrochloride 180 mg , montelukast sodium 10 mg , placebo</brief_summary>
	<brief_title>Single-Center , Double-Blind , Randomized , Parallel Study Comparing Onset Action , Efficacy &amp; Safety Single-Dose Fexofenadine HCl 180 mg v Montelukast Na 10 mg &amp; Placebo Treating Seasonal Allergic Rhinitis Subjects Allergen Exposure Unit</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Male female subject , 15 year age old History seasonal allergic rhinitis ( SAR ) fall pollen season , least previous 2 year History positive response antihistamine symptom SAR Must skin test positive ragweed within last 15 month least moderate reaction define wheal 7 mm great diluent wheal intradermal skin test wheal 5 mm great diluent wheal skin prick test . A skin test perform previous 15 month may use qualify patient perform investigator 's site record subject 's medical record All female must negative urine pregnancy test screen visit Willing able adhere visit schedule study requirement Clinically significant medical condition ( cardiovascular , hepatic , neurologic , hematological , renal , gastrointestinal , endocrine , major systemic disease ) , , judgment investigator , might interfere study , require treatment make implementation protocol interpretation study result difficult Asthma require treatment medication inhale , shortacting beta agonist asthma exacerbate exposure ragweed pollen Pregnancy breastfeed History hypersensitivity study medication drug similar chemical structure Nasal structural abnormality , include large nasal polyp mark septal deviation , significantly interfere nasal air flow Likelihood require treatment study period drug permit study protocol Upper low respiratory infection within 14 day first prim visit Diagnosis sinusitis within 30 day first prim visit Immunotherapy , except constant dose immunotherapy maintain throughout study Treatment investigational drug last 30 day study entry Recent history drug alcohol abuse Mental condition render subject unable understand nature , scope , possible consequence study Unlikelihood comply protocol uncooperative attitude inability return followup visit complete study Subjects randomize trial eligible participate another fexofenadine hydrochloride 180 mg v montelukast sodium 10 mg onset action study ( plan conduct 2003 ) Subjects research employee relatives study site staff involve study read protocol</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>